Bleeding after percutaneous coronary intervention: can we still ignore the obvious?

Mony Shuvy,1 Dennis T Ko1,2,3

Percutaneous coronary intervention (PCI) is the most common cardiac invasive procedure to treat patients with coronary artery disease. In the USA, it is estimated that more than one million patients undergo PCI each year. Fearsome complications such as coronary dissection or acute vessel closure in the balloon angioplasty era have been largely mitigated with the introduction of coronary artery stents and the routine use of antiplatelet and antithrombotic therapy. In the contemporary practice of interventional cardiology, it is recognised that bleeding has become the most common early complication associated with PCI. While the incidence of bleeding varies across studies, recent data from the USA found major bleeding occurs at a rate of 1.7% after PCI,1 about half from the site of arterial access and half from non-access locations, most commonly the gastrointestinal (GI) tract.1

As a practising clinician, it is easy to remember situations where a patient has undergone successful PCI and then suffered a major bleeding episode. Treating patients who bled after PCI is often complicated because one needs to consider the appropriate intervention to manage the active bleeding, to weigh the potential benefits and risks of withholding or withdrawing antiplatelet or anticoagulation therapy and to evaluate whether red blood cell transfusion outweighs its potential adverse effects. Indeed, many factors directly relating to the bleeding itself and its management have been implicated to be associated with worse outcomes among patients who experienced bleeding after PCI procedures.2

In this issue of Open Heart, Kwok et al3 make an important contribution to this field, by examining the relationship between bleeding complications in PCI and subsequent death. This comprehensive systematic review is one of the largest to date, with 38 published studies, and more than 500 000 patients. Their work reveals several important insights. First, the authors found that major bleeding with PCI is associated with more than threefold increase in death or major adverse cardiac outcome. This increased risk was sustained even after 12 months after the procedure, suggesting the long-lasting adverse impact of the bleeding event. Second, although it has been suggested that the adverse impact of bleeding may simply be a surrogate for patients with multiple comorbidities, the authors found increased risk associated with PCI bleeding even after consideration of confounding factors, suggesting that bleeding is independently linked to mortality and adverse cardiac outcomes after PCI. Finally, the authors found that the strength of association between PCI bleeding with death varied significantly according to the definition of bleeding used in the individual studies. This information could be particularly helpful for quality improvement initiatives to select a bleeding definition that maximises detection, while at the same time that is also meaningful to predict adverse outcomes. To complement these data, Marso and colleagues conducted an analysis that included more than three million PCI procedures in the USA and found that 12.1% of all in-hospital deaths after PCI are attributed to bleeding episodes.1 Furthermore, they demonstrated that bleeding was harmful in patients at different bleeding risks. Given the importance of bleeding after PCI, several aspects that may reduce the risk of bleeding should be considered in all patients.1

ARTERIAL ACCESS SITE

The radial artery is a superficial artery that is readily compressible compared with the femoral artery, which is in a much deeper location and with a harder to achieve haemostasis. Accordingly, performing PCI via the
APPROPRIATE ANTIPLATELET AND ANTITHROMBOTIC THERAPY

Dual antiplatelet therapy with aspirin and clopidogrel has been the mainstay treatment for the majority of patients with ACS and those undergoing PCI procedures. Recently, more potent antiplatelet drugs such as prasugrel and ticagrelor have been shown to be associated with additional benefit compared with clopidogrel in the management of patients with ACS. However, both medications are associated with an increased risk of bleeding.6 For prasugrel, it is important to note that there was no net clinical benefit for patients of 75 years or older or patients weighing less than 60 kg, and harm was observed for patients who had a previous stroke or transient ischaemic attack.7 Furthermore, trials of newer antiplatelet agents were performed in patients with ACS and not for patients with stable coronary disease undergoing PCI.

Evidence continues to evolve regarding the optimal duration for dual antiplatelet therapy after PCI. Practice guidelines from the USA currently recommend 12 months of dual antiplatelet therapy for ACS and drug-eluting stents implementation and a minimum of 1 month but ideally 12 months for bare metal stents.8 Another clinical dilemma is the optimal antiplatelet regimen in patients who require long-term anticoagulation therapy which is associated with substantial risk of bleeding and should be minimised if possible.2 Post PCI GI bleeding is a common problem, in particular, in patients with ACS.

For antithrombotic therapy with PCI, there is also a great complexity because of the vast number of choices that include heparin, heparin and glycoprotein IIb/IIIa inhibitors, low molecular weight heparin, fondaparinux, bivalirudin and others. In the Acute Catheterisation and Urgent Intervention Triage Strategy (ACUITY) trial, 13 819 patients with ACS were randomised and demonstrated that bivalirudin was associated with an approximately 50% reduction in bleeding complications compared with the glycoprotein IIb/IIIa group, with similar ischaemic adverse events.9

The appropriate use of antiplatelet and antithrombotic therapy should be individualised because it requires careful consideration to balance the risks of bleeding from these agents with their potential benefits depending on the clinical presentations. Factors that have been consistently shown to be associated with higher risk of PCI-associated bleeding include older age, female sex, body mass index at the extremes (overweight or underweight), acute presentation (STEMI, shock, cardiac arrest) and medical comorbidities (renal failure, prior bleeding, anaemia).2 10 Investigators have also developed bleeding risk scores to predict chance of bleeding risk PCI, which can be used at the beside to facilitate discussion of risk of bleeding with patients and potentially assist in treatment decisions.10 11

VASCULAR CLOSURE DEVICES

Although vascular closure devices are sometimes considered as a bleeding reduction strategy for patients with femoral access, early studies comparing vascular closure devices and manual compression have suggested an overall higher risk of vascular complication.8 In contrast, recent larger registries have suggested that the use of vascular closure devices is associated with lower risk of bleeding and vascular complications. It is difficult to provide a conclusive statement. In addition, it is difficult to distil the literature on vascular closure device because they have evolved substantially over time and few conclusive randomised studies are available. Accordingly, practice guidelines recommend vascular closure devices for early haemostasis and faster ambulation, but do not recommend for the purpose of decreasing vascular complications, including bleeding.8

In summary, in view of the wealth of evidence demonstrating the adverse effect of bleeding after PCI, it is time that clinicians become proactive to minimise the chance of bleeding after PCI by adopting the latest evidence in clinical practice to improve the outcome of our patients.

Funding DTK is supported by a Clinician Scientist Award from the Heart and Stroke Foundation of Canada, Ontario provincial office.

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
REFERENCES


